DK1793855T4 - Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom - Google Patents

Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom Download PDF

Info

Publication number
DK1793855T4
DK1793855T4 DK05783732.0T DK05783732T DK1793855T4 DK 1793855 T4 DK1793855 T4 DK 1793855T4 DK 05783732 T DK05783732 T DK 05783732T DK 1793855 T4 DK1793855 T4 DK 1793855T4
Authority
DK
Denmark
Prior art keywords
synucleinopatic
prevention
treatment
amyloidogenic disease
amyloidogenic
Prior art date
Application number
DK05783732.0T
Other languages
English (en)
Other versions
DK1793855T3 (da
Inventor
Dale B Schenk
Eliezer Masliah
Manuel J Buttini
Tamie J Chilcote
Edward Rockenstein
Kate Dora Games
Original Assignee
Prothena Biosciences Ltd
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35908081&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1793855(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/915,214 external-priority patent/US8697082B2/en
Application filed by Prothena Biosciences Ltd, Univ California filed Critical Prothena Biosciences Ltd
Publication of DK1793855T3 publication Critical patent/DK1793855T3/da
Application granted granted Critical
Publication of DK1793855T4 publication Critical patent/DK1793855T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05783732.0T 2004-08-09 2005-08-09 Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom DK1793855T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/915,214 US8697082B2 (en) 2002-11-01 2004-08-09 Prevention and treatment of synucleinopathic and amyloidogenic disease
US11/185,907 US8506959B2 (en) 2002-11-01 2005-07-19 Prevention and treatment of synucleinopathic and amyloidogenic disease
PCT/US2005/028166 WO2006020581A2 (en) 2004-08-09 2005-08-09 Prevention and treatment of synucleinopathic and amyloidogenic disease

Publications (2)

Publication Number Publication Date
DK1793855T3 DK1793855T3 (da) 2019-02-11
DK1793855T4 true DK1793855T4 (da) 2022-02-28

Family

ID=35908081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05783732.0T DK1793855T4 (da) 2004-08-09 2005-08-09 Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom

Country Status (22)

Country Link
US (2) US8506959B2 (da)
EP (2) EP3369433A1 (da)
JP (1) JP5211290B2 (da)
KR (2) KR101340417B1 (da)
AU (1) AU2005273969B2 (da)
BR (1) BRPI0514199A (da)
CA (1) CA2576672C (da)
CY (1) CY1121408T1 (da)
DK (1) DK1793855T4 (da)
ES (1) ES2705586T5 (da)
HR (1) HRP20190008T4 (da)
HU (1) HUE041974T2 (da)
IL (2) IL181061A (da)
LT (1) LT1793855T (da)
ME (1) ME03302B (da)
NO (1) NO20071267L (da)
NZ (1) NZ553621A (da)
PL (1) PL1793855T5 (da)
PT (1) PT1793855T (da)
RS (1) RS58421B2 (da)
SI (1) SI1793855T2 (da)
WO (1) WO2006020581A2 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
DK2426143T3 (da) 2007-01-05 2017-09-11 Univ Zuerich Fremgangsmåde til tilvejebringelse af sygdomsspecifikke bindingsmolekyler og mål
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PT2118300E (pt) * 2007-02-23 2015-09-22 Univ California Prevenção e tratamento da doença sinucleinopática e amiloidogénica
CA2678963C (en) * 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101265297B (zh) * 2007-03-15 2012-08-15 中国科学院上海生命科学研究院 α-突触核蛋白与Sph1的相互作用位点及其在筛选帕金森症药物中的应用
AU2015249034B2 (en) * 2007-12-28 2017-07-27 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
AU2008345022B2 (en) * 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
WO2009128948A1 (en) * 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
EP2282758B1 (en) * 2008-04-29 2018-11-21 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
ES2544569T3 (es) 2008-12-19 2015-09-01 Biogen International Neuroscience Gmbh Autoanticuerpos humanos anti alfa-sinucleina
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
RU2555526C2 (ru) 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
KR101308898B1 (ko) * 2011-02-08 2013-09-23 건국대학교 산학협력단 신규 항-α-시누클레인 단일클론항체 및 이를 이용한 ＥＬＩＳＡ 시스템
JP6061922B2 (ja) * 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
DK2723379T3 (da) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh Anti-alpha-synuklein-bindende molekyler
PT3378535T (pt) 2011-10-28 2023-02-06 Prothena Biosciences Ltd Anticorpos humanizados que reconhecem a alfa-sinucleína
BR112014018561A8 (pt) 2012-01-27 2017-07-11 Neotope Biosciences Ltd Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
KR20140077567A (ko) * 2012-12-14 2014-06-24 건국대학교 산학협력단 세포외 α-시누클레인 제거와 관련된 질환 치료용 조성물 및 그 치료제 스크리닝 방법
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
ES2890073T3 (es) 2015-08-25 2022-01-17 Prothena Biosciences Ltd Métodos para detectar alfa-sinucleína fosforilada
EP3207925A1 (en) * 2016-02-22 2017-08-23 Universität Wien Compound for use in the prevention and treatment of neurodegenerative diseases
HUE050096T2 (hu) * 2015-11-30 2020-11-30 Univ Wien Vegyület alkalmazásra neurodegeneratív betegségek megelõzésére és kezelésére
PT3463435T (pt) 2016-06-02 2021-11-22 Medimmune Ltd Anticorpos para alfa-sinucleína e as suas utilizações
CA3043651A1 (en) 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
JP7144755B2 (ja) * 2016-12-16 2022-09-30 ハー・ルンドベック・アクチエゼルスカベット 薬剤、使用および方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2019040612A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AR121918A1 (es) 2020-04-24 2022-07-20 Hoffmann La Roche Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
WO2021260434A1 (en) 2020-06-26 2021-12-30 Bioarctic Ab α-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES
KR102513116B1 (ko) 2021-06-03 2023-03-22 고려대학교 산학협력단 알파시뉴클레인-금나노입자 복합체, 이의 제조방법 및 이를 이용한 약물 스크리닝 방법

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US6093406A (en) 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
CA2081482C (en) 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
CA2112578C (en) 1991-07-03 2000-10-10 Yasuhiro Ogawa Thermoplastic polyurethane elastomer, process for producing same, apparatus for producing same and elastomer fibers made from same
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ES2097925T3 (es) 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
AU686579B2 (en) 1992-10-01 1998-02-12 Cold Spring Harbor Laboratory Complex combinatorial chemical libraries encoded with tags
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
AU705889B2 (en) 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
WO1995012608A1 (en) 1993-11-02 1995-05-11 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5807741A (en) 1995-07-20 1998-09-15 Brown; Douglas Richard Neutralizing monoclonal antibody against botulinum neurotoxin serotype F
PT859959E (pt) 1995-11-10 2003-12-31 Elan Corp Plc Peptidos que aumentam o transporte atraves dos tecidos e metodos para a sua identificacao e utilizacao
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
WO1998025387A2 (en) 1996-12-03 1998-06-11 Northern Telecom Limited Call center integration with operator services databases
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
WO1998059050A1 (en) 1997-06-25 1998-12-30 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Cloning of a gene mutation for parkinson's disease
EP1001987B1 (en) 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) * 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
ATE315645T1 (de) 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
NZ507727A (en) 1998-05-21 2003-11-28 Univ Tennessee Res Foundation Methods for amyloid removal using anti-amloid antibodies
US6184351B1 (en) 1998-09-25 2001-02-06 Amgen Inc. α-synuclein super-mutants accelerate α-synuclein aggregation
AU6288499A (en) 1998-10-06 2000-04-26 Regents Of The University Of California, The Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
US6172122B1 (en) 1998-12-17 2001-01-09 The Lubrizol Corporation Stable emulsions from gelled overbased substrates with surfactants and aqueous liquids
US20040146521A1 (en) 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001006989A2 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
GB9924513D0 (en) 1999-10-15 1999-12-15 Novartis Ag Organic compounds
US6557129B1 (en) 1999-11-23 2003-04-29 Janusz Rajski Method and apparatus for selectively compacting test responses
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
AU2001238612A1 (en) 2000-02-18 2001-08-27 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
DE60114157T2 (de) 2000-02-21 2006-06-29 Pharmexa A/S Verfahren zur herabregulierung von amyloid
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア　ファーマシューティカルズ　インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020160394A1 (en) 2001-01-24 2002-10-31 Bayer Corporation Regulation of transthyretin to treat obesity
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2003037712A1 (fr) * 2001-11-01 2003-05-08 Ishigaki Company Limited Dispositif de propulsion par jet d'eau utilise dans un bateau
EP1451217A4 (en) 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
AU2002357007A1 (en) 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
GB0216972D0 (en) 2002-07-22 2002-08-28 Univ Lancaster Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
US7138255B2 (en) 2002-09-30 2006-11-21 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (da) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20150095800A1 (en) 2013-09-30 2015-04-02 Microsoft Corporation Prioritizing communications based on communication patterns

Also Published As

Publication number Publication date
PL1793855T3 (pl) 2019-07-31
EP1793855A2 (en) 2007-06-13
WO2006020581A9 (en) 2006-03-30
DK1793855T3 (da) 2019-02-11
EP1793855B1 (en) 2018-11-14
BRPI0514199A (pt) 2008-06-03
AU2005273969A1 (en) 2006-02-23
CA2576672A1 (en) 2006-02-23
IL181061A (en) 2014-12-31
CA2576672C (en) 2015-06-02
KR101340417B1 (ko) 2013-12-13
SI1793855T1 (sl) 2019-04-30
RS58421B1 (sr) 2019-04-30
PT1793855T (pt) 2019-02-13
US20100031377A1 (en) 2010-02-04
ES2705586T5 (es) 2022-05-06
AU2005273969B2 (en) 2011-05-26
EP3369433A1 (en) 2018-09-05
LT1793855T (lt) 2019-02-11
PL1793855T5 (pl) 2022-05-30
ME03302B (me) 2019-07-20
RS58421B2 (sr) 2022-05-31
CY1121408T1 (el) 2020-05-29
EP1793855A4 (en) 2009-04-22
ES2705586T3 (es) 2019-03-26
KR20130054426A (ko) 2013-05-24
AU2005273969A2 (en) 2006-02-23
US20060058233A1 (en) 2006-03-16
WO2006020581A2 (en) 2006-02-23
NZ553621A (en) 2010-01-29
IL235725B (en) 2018-08-30
IL181061A0 (en) 2007-07-04
SI1793855T2 (sl) 2022-04-29
HRP20190008T1 (hr) 2019-04-05
KR20070042566A (ko) 2007-04-23
JP2008509223A (ja) 2008-03-27
US8506959B2 (en) 2013-08-13
NO20071267L (no) 2007-05-09
JP5211290B2 (ja) 2013-06-12
EP1793855B2 (en) 2022-01-19
HUE041974T2 (hu) 2019-06-28
HRP20190008T4 (hr) 2022-04-01
WO2006020581A3 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
DK1793855T4 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK3067066T3 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
NO2017017I1 (no) umeklinidium og vilanterol
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK3321359T3 (da) Variante former af uratoxidase og anvendelse deraf
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK2075000T3 (da) Kombination af azelastin og ciclesonid
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
DK1831154T3 (da) Fremstilling af pregabalin og relaterede forbindelser
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK2952178T3 (da) Oftalmiske sammensætninger og fremgangsmåder til behandling af øjne
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DK1732892T3 (da) Tetrahydrocarbazoler og derivater
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
DK1744781T3 (da) Behandling af infektionssygdomme